Oleg Gluz, ESMO 2022: Analysis of ADAPT and ADAPTcycle trials – Endocrine therapy response in breast cancer
The benefit of chemotherapy addition to endocrine therapy remains controversial in premenopausal patients. In this touchONCOLOGY interview Dr Oleg Gluz (West German Study Group, Mönchengladbach, Germany) discusses the ongoing phase III ADAPT cycle trial investigating the impact of age, recurrence score, and ovarian function suppression on endocrine therapy response.
The abstract entitled ‘Impact of age, recurrence score (RS) and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Analysis of ADAPT and ADAPTcycle trials‘ Abstract LBA14, was presented at European Society for Medical Oncology (ESMO) 2022.
- What controversy persists around the addition of chemotherapy to endocrine therapy in premenopausal women with breast cancer? (0:26)
- Could you tell us a little about the ADAPT and ADAPTcycle clinical trials? (3:05)
- What were the aims and design of the current analysis? (5:09)
- What were the findings of the analysis? (7:50)
Disclosures: Oleg Gluz is on the advisory board for Roche, Lilly, Amgen, Novartis, Pierre Fabre, MSD, Celgene, Pfizer, Gilead, Molecular Health, Seagen; and has financial interests, and is an invited speaker for AstraZeneca, Exact Science, and Roche.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.
Filmed in coverage of ESMO 2022
Share this Video
Related Videos In Breast Cancer
Sara Hurvitz, SABCS 2022: Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2+ metastatic breast cancer: DESTINY-Breast03
Trastuzumab deruxtecan (T-DXd) is approved in the United States and European Union for use in patients with HER2+ unresectable/metastatic breast cancer. Approval was based on the randomized, multicenter, open-label, phase III DESTINY-Breast03 (NCT03529110) trial. In this interview we discuss with Dr Sara Hurvitz (David Geffen School of Medicine, UCLA Los Angeles, CA, USA) updated data […]
Erika Hamilton, SABCS 2022: Trastuzumab deruxtecan and pertuzumab in HER2+ metastatic breast cancer
Preclinical findings have suggested that when used in combination with anticancer treatments, trastuzumab deruxtecan (T-Dxd) could improve treatment efficacy in HER2+ metastatic breast cancer (mBC). In this interview we discuss with Dr Erika Hamilton (Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN) preliminary data from the dose expansion phase of the DESTINY-Breast07 (DB-07) (NCT04538742) trial. […]
Sudeep Gupta, SABCS 2022: Addition of platinum to neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial
The impact of adding platinum on long-term outcomes in triple-negative breast cancer (TNBC) has not been definitively established. The controlled, single-centre, phase III study conducted by Tata Memorial Hospital in Mumbai, India evaluated the efficacy and toxicity of adding platinum to standard neoadjuvant chemotherapy in patients with triple-negative breast cancer. In this touchONCOLOGY interview, we speak […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!